Redeye makes minimal estimate adjustments following the Q3’23 report, in which the reported figures were mainly in line with our estimates. While the present market conditions present ongoing challenges, we are optimistic that the new AI-based drug product has the potential to be a transformative innovation and a game changer for Kontigo Care. We have slightly adjusted our fair value range, primarily driven by the impact of increased interest rates.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Kontigo Care - Resilient top-line

© Modular Finance, source Nordic Press Releases